Reference number(s)
2989-A

Specialty Guideline Management
Fibryga

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Fibryga	fibrinogen [human]

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-approved Indications[1]

Fibryga is indicated for:

- Fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency.
- The treatment of acute bleeding episodes in adults and children with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Limitation of use

Fibryga is not indicated for dysfibrinogenemia.

All other indications are considered experimental/investigational and not medically necessary.

Coverage Criteria

Congenital Fibrinogen Deficiency[1,2]

Authorization of 1 month may be granted for treatment of acute bleeding episodes in members with a diagnosis of congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

Acquired Fibrinogen Deficiency[1]

Authorization of 1 month may be granted for treatment of bleeding episodes in members with a diagnosis of acquired fibrinogen deficiency.

Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must meet all requirements in the coverage criteria section.

References

1. Fibryga [package insert]. Paramus, NJ: Octapharma USA, Inc.; July 2024.
2. National Hemophilia Foundation. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Selected Disorders of the Coagulation System. Revised April 2024. MASAC Document #284. https://www.bleeding.org/sites/default/files/document/files/MASAC-Products-Licensed.pdf. Accessed October 15, 2024.